Track topics on Twitter Track topics that are important to you
Label-free Agile R100 demonstrates detection of Zika antigen at 10 times lower concentration than Octet.
San Diego, CA (PRWEB) June 20, 2017
Nanomedical Diagnostics, a life science company pioneering label-free graphene biosensors for use in drug discovery, today announced that the paper, “Towards Novel Graphene-Enabled Diagnostic Assays with Improved Signal-to-Noise Ratio,” which features Agile R100’s significant increase in signal-to-noise ratio over Bio-Layer Interferometry (BLI) and ELISA platforms, has been published in MRS Advances, a journal that highlights new and emerging science. The paper compares Zika antigen detection on an Agile R100 versus an Octet RED96, a BLI platform. It also compares measurement of an inflammatory protein, IL-6, with an Agile R100 versus with an Invitrogen ELISA kit.
While BLI and ELISA are widely used in drug discovery and disease diagnostics, the platforms suffer noise interference at ultra-low concentrations, which reduces measurement sensitivity. Highly-sensitive measurements are necessary to develop biopharmaceuticals at therapeutically-relevant levels and to gain accurate early clinical results. In this study, Agile R100 exhibited detection of Zika viral antigen at a concentration 10 times lower than on the Octet RED96, a standard kinetic binding drug discovery platform. Similarly, Agile R100 lowered the limit of detection for inflammatory protein IL-6 by 10 times, versus on an ELISA, a conventional tool for clinical diagnostics.
“This study has broad-ranging healthcare implications,” says Nanomedical Diagnostics CEO, Ross Bundy. “The Octet is an expensive machine that is costly to run, plus requires extensive training. ELISAs are time-consuming and technically onerous. Agile R100 is a benchtop label-free assay that cuts out numerous steps typical of an ELISA, and provides kinetic binding data in agreement with the Octet at a fraction of the cost. Researchers now have access to an intuitive, highly-sensitive, quantitative platform to accelerate drug development and disease research.”
Agile R100, an easy-to-use benchtop kinetic binding assay built with cutting-edge proprietary Field Effect Biosensing (FEB) technology, employs an electrical form of measurement rather than optical methodologies as BLI and ELISA utilize. The 10x increase in signal-to-noise of Agile R100 over conventional optical methods represents a significant advancement in drug development and highlights the potential for future clinical capabilities.
About Nanomedical Diagnostics
Nanomedical Diagnostics (“Nanomed”) is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that provides real-time label-free kinetic binding and affinity data. Unique graphene biosensors at the heart of the assay deliver highly-sensitive kinetic characterization of small molecules in complex media such as DMSO, using unprecedentedly small amounts of sample, making the platform a novel orthogonal technique for drug discovery hit validation and lead optimization.
For the original version on PRWeb visit: http://www.prweb.com/releases/Nanomedical_Diagnostics/MRS_publication/prweb14439737.htmNEXT ARTICLE
Bioscience - any of the sciences that deal with living organisms. The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Immunoassay - ELISA
Immunoassays are quick and accurate tests to detect specific molecules. Immunoassays rely on an antibody to bind to the specific structure of a molecule. Antibodies are proteins generated by animals in response to the invasion of a foreign molecule (anti...